Quality of Life in Patients With Bladder Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00553215|
Recruitment Status : Unknown
Verified February 2010 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : November 5, 2007
Last Update Posted : January 10, 2014
RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future.
PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.
|Condition or disease||Intervention/treatment|
|Bladder Cancer||Procedure: quality-of-life assessment Procedure: questionnaire administration|
- To study the effects of recurrence and progression on health-related quality of life (HRQL).
- To study the effects of repeat cystoscopy on HRQL.
- To study the patients' assessments of a hypothetical prognostic model and how this affects their preference for the mode of surveillance.
OUTLINE: This is a multicenter study.
Quality-of-life questionnaires developed by the European Organization for Research and Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to muscle-invasive bladder cancer will be combined and used in conjunction with the general cancer questionnaire QLQ-C30.
Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients. Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first routine follow-up and annually until the end of study.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
|Study Type :||Observational|
|Enrollment :||2700 participants|
|Official Title:||Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]|
|Study Start Date :||December 2005|
- Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00553215
|University of Birmingham||Recruiting|
|Birmingham, England, United Kingdom, B15 2TH|
|Contact: Maurice Zeegers, MD 44-121-414-6721|
|Study Chair:||Maurice Zeegers, MD||University of Birmingham|